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Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with
active epilepsy: Cohort study using the General Practice Research Database
Jennifer M. Nicholas a,*, Leone Ridsdale b, Mark P. Richardson b, Andy P. Grieve a, Martin C. Gulliford a
aDepartment of Primary Care and Public Health Sciences, King’s College London, United Kingdom
b Institute of Psychiatry, King’s College London, United Kingdom
1. Introduction
As the population ages, fractures related to poor bone health are
a growing public health concern.1 Projections for the UK suggest
approximately 203 000 osteoporotic fractures by 2010 with
medical costs of £1.9 billion, increasing to 230 000 fractures by
2020 costing £2.2 billion.2 The incidence of fracture in people with
epilepsy is twice that in those without epilepsy,3 at around 24
fractures per 100 000 person-years.4 This higher incidence may be
partly attributable to increased risk of injury due to seizures and
increased risk of falls resulting from adverse effects of antiepileptic
drugs (AEDs), such as visual disturbances, dizziness, vertigo and
motor disturbances.5 There is also increasing evidence that AEDs
that induce cytochrome P450 (CYP450) system of liver enzymes
(Table 1) have adverse effects on bone health, which could increase
fracture risk.6,7 Induction of liver enzymes increases metabolism of
vitamin D leading to decreased absorption of dietary calcium.6 As
higher levels of parathyroid hormone are required to increase the
release of stored vitamin D there is also an increase in bone
turnover.7 From observed decreases in bone density mineral
density with liver enzyme inducing (LEI) AED treatment, it is
suggested that the relative risk for any fracture may be in the
region of 1.2–1.3.3
Several non-randomized studies have found that people using
both LEI AEDs and non LEI AEDs have increased fracture risk.8–12
The majority of these studies compared AED users to a control
group without active epilepsy, so the association between AEDs
and fracture may be confounded by the increased risk of injury for
people with epilepsy. The single study conducted in patients with
active epilepsy found that there was a small but non-signiﬁcant
increase in the odds of fracture with LEI AED treatment in
comparison to treatment with other AEDs (OR 1.15; 95% CI: 0.87–
1.52), with weak evidence that the effect may be greater for
women than men.9
To examine the relationship between use of LEI AEDs and
fracture risk in men and women with active epilepsy, we
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Purpose: Liver enzyme inducing antiepileptic drugs (LEI AEDs) have adverse effects on bone metabolism
but it is unclear whether this translates into increased fracture risk. This population based cohort study
aimed to evaluate whether treatment with LEI AEDs is associated with increased risk of fracture in
people with active epilepsy.
Methods: The cohort included patients diagnosed with epilepsy and prescribed AEDs while registered at
a GPRD general practice during 1993–2008. The hazard ratio with current use of LEI AEDs for fracture at
any site and hip fracture was estimated using Cox proportional hazards models.
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fracture (1.15–1.94; p = 0.002). In men, the hazard ratio for fracture was 1.09 (0.98–1.20; p = 0.123) and
for hip fracture 1.53 (1.10–2.12; p = 0.011). For every 10 000 women treated with LEI AEDs for one year,
there could be 48 additional fractures, including 10 additional hip fractures. For every 10 000 men
treated with LEI AEDs for one year, there could be 4 additional hip fractures.
Conclusions: LEI AEDs may increase the risk of fracture in people with epilepsy. In patients at high risk of
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undertook a retrospective cohort study using the United Kingdom
(UK) General Practice Research Database (GPRD). The GPRD is a
large database of anonymized longitudinal electronic medical
records from general practices throughout the UK.13 It includes
information on demographics, medical diagnoses, referrals, test
results and prescriptions for approximately 10 million participants
from around 600 general practices throughout the UK, with data on
over 4.8 million active participants. The sample size enabled by
GPRD allows a more precise estimate of the fracture risk with use
of LEI AEDs allowing greater understanding of the magnitude of
any increase in risk.
2. Methods
2.1. Participants
This cohort study used data from general practices contrib-
uting to the GPRD between 1 January 1993 and 15 October 2008.
For entry into the GPRD, practice data must be up to standard
(UTS) for research as set out by the GPRD group. Independent
studies have also evaluated the validity of GPRD diagnostic
coding with satisfactory results. The positive predictive value in
GPRD has been found to be 88.1% for vertebral fracture and
91.0% for hip fracture14 and the median positive predictive value
for diagnostic coding has been found to be 88.6% across disease
groups.15
Participants were included in the study cohort if they had ever
had a recorded diagnosis of epilepsy and also had received one or
more prescriptions for AEDs after they were registered with a
GPRD practice. Date of onset of epilepsy was deﬁned as the earliest
date at which a participant had a recorded diagnosis of epilepsy or
prescription of AEDs.
Participant follow-up started on the date of ﬁrst AED
prescription after the later of: date of onset of epilepsy, date of
registration with a GPRD practice, date at which the practice began
contributing UTS data to GPRD, or 1 January 1993. Participant
follow-up was censored if the participant died or transferred out of
a GPRD practice, or at the last date at which their practice
contributed UTS data to GPRD. To restrict the sample to follow-up
when participants had active epilepsy, only AED treated follow-up
was included for each participant.
2.2. Exposures
Treatment was ascertained from recorded prescriptions written
for patients by their general practice. To allow for changes in
epilepsy medication exposure over time, participant follow-up was
split into treatment episodes (Fig. 1).16 A new treatment episode
started with each change in combination of AED prescriptions. The
episode continued while each subsequent prescription for the
same medication(s) was recorded within 90 days of the previous
prescription. The episode ended when the combination of
medications changed: either 90 days after the last prescription
of that combination; or if an additional medication was also
prescribed. For all analyses, participants were categorized as
either: AED treatment includes one or more LEI AED; or AED
treatment includes only non-LEI AEDs.
2.3. Outcomes
Outcomes were determined from predeﬁned lists of medical
and referral codes. The primary outcome was diagnosis of fracture.
The secondary outcome was diagnosis of hip fracture. After the
initial fracture event, any subsequent fracture codes recorded less
than 14 days after the initial code were assumed to relate to
continuing treatment for the initial fracture. If a subsequent
fracture code was recorded at least 14 days, but less than six
months, after the initial fracture code then this was assumed to
relate to continuing treatment for the initial fracture if the initial
and subsequent codes indicated the same fracture site or either
code did not indicate a fracture site. All other fracture codes were
assumed to indicate incident fracture events.
2.4. Possible confounding variables
Potential confounders were identiﬁed from the published
literature, including variables from two models that aim to predict
the risk of osteoporotic or hip fracture over ten years.17,18 For each
participant follow-up was split to allow a time dependent
Table 1
Antiepileptic drugs.
Liver enzyme inducing Non liver enzyme inducing
Carbamazepine, oxcarbazepine,
phenobarbital, phenobarbital
sodium, methylphenobarbital,
phenytoin, fosphenytoin sodium,
topiramate, primidone
Ethosuximide, mesuximide,
clobazam, clonazepam, gabapentin,
pregabalin, vigabatrin, tiagabine,
valproic acid, sodium valproate,
sultiame, zonisamide, beclamide,
lamotrigine, lacosamide,
levetiracetam, ruﬁnamide, stripentol
Fig. 1. Deﬁnition of time-varying treatment over follow-up for an example participant.
J.M. Nicholas et al. / Seizure 22 (2013) 37–4238
categorical variable for current age (11 categories: <5, 5 to <10, 10 to
<15, 15 to <25, 25 to <35, 35 to <45, 45 to <55, 55 to <65, 65 to <75,
75 to <85, 85+ years) and duration of epilepsy (6 categories: <1; 1 to
<5; 5 to <10; 10 to <15; 15 to <20; 20+ years). To avoid adjusting for
mediators of the relationship between LEI AED use and fracture, all
other confounders were only assessed at the start of each treatment
episode or immediately following an incident fracture event. This
means that these variables remained constant throughout each
episode and were only updated if there was a change in AED
treatment or if a fracture occurred. Categorical variables were used
to adjust for: previous use of LEI AEDs; the number of classes of AED
previously prescribed (6 categories: 0, 1, 2, 3–4, 5–6, 7+ classes);
number seizures or faints in the last three years prior to start of the
treatment episode (4 categories: 0, 1, 2, 3+); number of fractures in
last three years (3 categories: 0, 1, 2+); and number of falls in last
three years (3 categories: 0, 1, 2+). Adjustment was also made for
prior diagnoses of: cardiovascular disease; hypertension; respirato-
ry disease; renal failure; endocrine disease; digestive system
diseases; nervous system diseases; neoplasms; diseases of the
blood and blood forming organs; mental disorders; osteoporosis;
and musculoskeletal conditions. Confounders also included prior
prescription of the following medications: oral corticosteroids;
osteoporosis treatments; cardiovascular system medications; pro-
ton pump inhibitors; respiratory system medications; nervous
system medications; medications for infections; endocrine system
medications; medications used for the treatment of musculoskeletal
and joint diseases; medications used for anaesthesia; medications
used for malignant disease and immunosuppression.
2.5. Analysis methods
Data were analyzed in a time to event framework using Cox
proportional hazards models in Stata MP version 11.1 (Stata
corporation, College Station, TX, USA). Calendar time was used as
the time scale to allow adjustment for seasonal variation in
fracture risk, with the earliest possible entry date (1 January 1993)
used as the time origin in all analyses. The proportional hazards
assumption was evaluated for each variable by testing for a non-
zero slope in Schoenfeld residuals. As the proportional hazards
assumption was violated for the interaction between treatment
and gender, all models were ﬁtted separately for men and women.
Robust standard errors were used to account for clustering by
general practice.
The initial model for the primary outcome of fracture at any site
estimated the unadjusted hazard ratio for men and women
separately for comparison of AED treatment that includes one or
more LEI AED to the reference category of AED treatment that
includes only non-LEI AEDs. In order to provide a multiple regression
adjusted hazard ratio, the potential confounders listed previously
were entered into the model as categorical explanatory variables.
A pre-speciﬁed subgroup analysis was carried out for fracture at
any site in participants aged 50 and over, since fractures in this
group may be increasingly related to poor bone health rather than
high impact trauma. As with the primary analysis, models were
ﬁtted for men and women separately to estimate the hazard ratio
for current LEI treatment.
We also examined the secondary outcome of fracture of the hip
or neck of femur (henceforth referred to as hip fracture), which has
been evaluated as being highly attributable to poor bone health.19
For hip fracture, the same methods as for fracture at any site were
used to estimate unadjusted and multiple regression adjusted
hazard ratios for men and women of all ages. Fewer confounders
were used for adjustment in the analyses in participants aged 50
and over and when evaluating hip fracture, due to the smaller
number of outcomes. Full details of variables used for adjustment
in each analysis are available from the authors on request.
The number needed to treat to harm (NNTH) and absolute
increases in the risk of fracture were calculated based on the
predicted absolute risk without treatment and hazard ratio
following methods suggested by Altman and Andersen.20
3. Results
The cohort of participants with current epilepsy included
32 021 men and 31 238 women from 434 general practices. Total
follow-up was 140 133 person-years for men (median 2.93 years
per man), of which 95 027 person-years included treatment with
one or more LEI AED (median 2.90) and 45 106 person-years
where treatment included only non-LEI AEDs (median 1.75). In
women total follow-up was 138 660 person-years (median
2.97), with 88 512 person-years treated with LEI AEDs (median
2.85) and 50 148 person-years treated with only non-LEI AEDs
(median 1.80).
Participant characteristics for those who were treated with LEI
AEDs on entry into the study and those who were treated with non-
LEI AEDs on entry into the study are presented in Table 2. AED use
was relatively stable, with 64.2% of men and 62.1% of women
remaining on initial AED combination throughout follow-up.
3.1. Fracture at all sites
For men of all ages there were 3319 fractures in 2667
participants. In women of all ages there were 4037 fractures in
3133 participants. The evidence for an increase in fracture risk with
current use of LEI AEDs compared to current use of non-LEI AEDs
was stronger for women than for men (Table 3). The adjusted
hazard ratio for current use of LEI AEDs was consistent with a small
but non-signiﬁcant increase in risk of fracture in men (hazard ratio
1.09; 95% CI: 0.98–1.20; p = 0.123). For women there was stronger
evidence of a small increase in risk of fracture at any site with
current use of LEI AEDs (1.22; 1.12–1.34; p < 0.001). When the
sample was restricted to participants aged 50 and over, ﬁndings
were similar to those for all ages.
3.2. Hip fracture
In men there were 290 hip fractures in 275 participants. In
women there were 498 hip fractures in 469 participants. There was
a greater risk of hip fracture with current use of LEI AEDs compared
to current use of non-LEI AEDs for both men (adjusted hazard ratio
1.53; 1.10–2.12; p = 0.011) and women (1.49; 1.15–1.94;
p = 0.002). The hazard ratio was broadly similar between men
and women, and suggests that hazard ratio for hip fracture was of a
greater magnitude than that for fracture at all sites.
3.3. Population risks
In comparison to treatment with non-LEI AEDS, treatment with
LEI AEDs for one year was estimated to result in 48 extra fractures
per 10 000 women treated (95% CI: 26–71), including 10 additional
hip fractures (95% CI: 3–20). This gives number needed to treat to
harm (NNTH) of 209 (140–383) for any fracture and 962 (507–
3116) for hip fracture in women. In women aged 50 and over, one
year of treatment with LEI AEDs was estimated to result in 88 extra
fractures per 10 000 women treated (95% CI: 40–142), in
comparison to treatment with non-LEI AEDs, yielding NNTH of
113 (70–252). The lower NNTH for women aged over 50 reﬂects
the higher risk of fracture in this age group in comparison to
women of all ages.
It is not meaningful to estimate NNTH for fracture at all sites in
men, since the ﬁndings are consistent with current LEI AED
treatment having no impact on risk of fracture. However,
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compared to treatment with non-LEI AEDs, treatment with LEI
AEDs for one year was estimated to result in 4 additional hip
fractures per 10 000 men treated (95% CI: 1–9) with NNTH of 2429
(1148–12 516).
4. Discussion
This study found that current treatment with LEI AEDs was
associated with an increased risk of fracture for people with
Table 2
Baseline characteristics and changes in antiepileptic drugs for people prescribed liver enzyme inducing or non liver enzyme inducing antiepileptic drugs at start of follow-up.
Values are numbers (percentages) of patients unless stated otherwise.
Characteristics Men (N = 32 021) Women (N = 31 238)
Non-inducing Inducing All Non-inducing Inducing All
Median age at
start of follow-up, years
33.5 45.4 41.4 34.8 48.2 43.1
Onset of epilepsy prior to start of follow-up 9754 (79.6) 16 508 (83.5) 26 262 (82.0) 10 382 (78.9) 15 222 (84.2) 25 604 (82.0)
Median time since onset of epilepsy if before
start of follow-up, years
0.92 3.75 2.42 1.09 4.50 2.80
Year of start of follow-up
1993–1995 1877 (15.3) 6296 (31.9) 8173 (25.5) 2154 (16.4) 6007 (33.2) 8161 (26.1)
1996–1998 1628 (13.3) 3201 (16.2) 4829 (15.1) 1723 (13.1) 3091 (17.1) 4814 (15.4)
1999–2001 2671 (21.8) 4394 (22.2) 7065 (22.1) 2780 (21.1) 3939 (21.8) 6719 (21.5)
2002–2004 2754 (22.5) 3073 (15.6) 5827 (18.2) 2889 (22.0) 2702 (14.9) 5591 (17.9)
2005–2008 3331 (27.2) 2796 (14.1) 6127 (19.1) 3609 (27.4) 2344 (13.0) 5953 (19.1)
Diagnoses prior to start of follow-up
Fall in last three years 495 (4.0) 540 (2.7) 1035 (3.2) 763 (5.8) 776 (4.3) 1539 (4.9)
Fracture in last three years 2455 (20.0) 4082 (20.7) 6537 (20.4) 2212 (16.8) 3282 (18.1) 5494 (17.6)
Malnutrition, malabsorption, or liver disease 315 (2.6) 581 (2.9) 896 (2.8) 369 (2.8) 535 (3.0) 904 (2.9)
Hyperthyroidism, hyperparathyroidism,
or hypogonadism
64 (0.5) 80 (0.4) 144 (0.4) 162 (1.2) 218 (1.2) 380 (1.2)
Diabetes mellitus 553 (4.5) 803 (4.1) 1356 (4.2) 566 (4.3) 718 (4.0) 1284 (4.1)
Osteoporosis 67 (0.5) 118 (0.6) 185 (0.6) 288 (2.2) 430 (2.4) 718 (2.3)
Arthritis 1355 (11.1) 2395 (12.1) 3750 (11.7) 1797 (13.7) 2749 (15.2) 4546 (14.6)
Stroke or TIA 1319 (10.8) 2495 (12.6) 3814 (11.9) 1292 (9.8) 2172 (12.0) 3464 (11.1)
Cancer 1232 (10.0) 2375 (12.0) 3607 (11.3) 1773 (13.5) 2856 (15.8) 4629 (14.8)
Non-epilepsy nervous system and sense
organ diseases
5895 (48.1) 8620 (43.6) 14 515 (45.3) 6757 (51.4) 8792 (48.6) 15 549 (49.8)
Mental disorders 4376 (35.7) 6727 (34.0) 11 103 (34.7) 4953 (37.7) 6782 (37.5) 11 735 (37.6)
Prescriptions in prior 12 months
Corticosteroids 530 (4.3) 927 (4.7) 1457 (4.6) 647 (4.9) 1015 (5.6) 1662 (5.3)
Osteoporosis treatments 218 (1.8) 279 (1.4) 497 (1.6) 1106 (8.4) 1721 (9.5) 2827 (9.0)
Treatments for dementia 36 (0.3) 21 (0.1) 57 (0.2) 64 (0.5) 27 (0.1) 91 (0.3)
Drugs used in psychoses and related disorders 864 (7.0) 1629 (8.2) 2493 (7.8) 1110 (8.4) 1872 (10.4) 2982 (9.5)
Hypnotics and anxiolytics 1747 (14.2) 2922 (14.8) 4669 (14.6) 2140 (16.3) 3126 (17.3) 5266 (16.9)
Tricyclic and related antidepressants 710 (5.8) 1096 (5.5) 1806 (5.6) 1143 (8.7) 1650 (9.1) 2793 (8.9)
Other antidepressants 1052 (8.6) 1323 (6.7) 2375 (7.4) 1611 (12.2) 1707 (9.4) 3318 (10.6)
Opioid analgesics 1985 (16.2) 3293 (16.7) 5278 (16.5) 2779 (21.1) 4087 (22.6) 6866 (22.0)
Other analgesics 4000 (32.6) 6249 (31.6) 10 249 (32.0) 4953 (37.7) 6988 (38.6) 11 941 (38.2)
Parkinson’s medications 531 (4.3) 935 (4.7) 1466 (4.6) 646 (4.9) 1080 (6.0) 1726 (5.5)
Medications used for nutrition and
blood disorders
1318 (10.7) 2214 (11.2) 3532 (11.0) 1982 (15.1) 2806 (15.5) 4788 (15.3)
Changes in AED combination during follow-up
0 8629 (67.4) 11 936 (62.1) 20 565 (64.2) 8923 (65.3) 10 469 (59.6) 19 392 (62.1)
1 1170 (9.1) 2338 (12.2) 3508 (11.0) 1356 (9.9) 2196 (12.5) 3552 (11.4)
2 1007 (7.9) 1911 (9.9) 2918 (9.1) 1167 (8.5) 1886 (10.7) 3053 (9.8)
3 279 (2.2) 591 (3.1) 870 (2.7) 370 (2.7) 604 (3.4) 974 (3.1)
4 222 (1.7) 423 (2.2) 645 (2.0) 258 (1.9) 442 (2.5) 700 (2.2)
5 or more 400 (3.1) 861 (4.5) 1261 (3.9) 562 (4.1) 919 (5.2) 1481 (4.7)
Table 3
Hazard ratios for the association between risk of fracture and current use of liver enzyme inducing antiepileptic drugs compared to current use of non liver enzyme inducing
antiepileptic drugs.
Events Person-years Unadjusted Multiple regression adjusted
HR (95% CI) p-Value HR (95% CI) p-Value
Men
All fractures, all ages 3319 140 133 1.05 (0.96, 1.15) 0.257 1.09 (0.98, 1.20) 0.123
All fractures, ages 50+ 1405 60 157 1.20 (1.05, 1.38) 0.007 1.14 (0.98, 1.34) 0.091
Hip fractures, all ages 290 140 133 2.03 (1.50, 2.75) <0.001 1.53 (1.10, 2.12) 0.011
Women
All fractures, all ages 4037 138 660 1.41 (1.30, 1.52) <0.001 1.22 (1.12, 1.34) <0.001
All fractures, ages 50+ 2814 63 520 1.17 (1.07, 1.29) <0.001 1.23 (1.11, 1.38) <0.001
Hip fractures, all ages 498 138 660 1.68 (1.38, 2.06) <0.001 1.49 (1.15, 1.94) 0.002
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epilepsy, with stronger evidence for an increased risk for women
than for men. The hazard ratio for hip fracture was greater than
that observed at all sites, with an increased risk of hip fracture
observed for both men and women. As the risk of fracture varies
substantially between age groups,4 the number needed to treat to
cause one additional fracture also changes. For those who are at
low risk of fracture, a large number of people would need to be
treated with LEI AEDs to cause one additional fracture. However,
for people at high baseline risk of fracture, such as women of older
age, the number needed to treat with LEI AEDs to cause one
additional fracture may be more modest.
4.1. Comparison to other studies
The only previous study to make a direct comparison of LEI and
non-LEI AEDs in patients with active epilepsy also found a small
but non-signiﬁcant increase in fracture risk with use of LEI AEDs
(OR 1.15; 95% CI: 0.87–1.52).9 Our study, which had greater power,
added to these ﬁndings and provided stronger evidence that use of
LEI AEDs is associated with greater fracture risk in people with
active epilepsy. Although we estimated models separately for men
and women, we found that there was only limited evidence that
the relative risk differs between genders, which agrees with
previous ﬁndings.9 Souverein and colleagues9 also reported an
increased fracture risk with use of valproate, in addition to
carbamazepine, phenobarbital, and phenytoin. We did not
examine the separate effects of different AEDs, so we cannot
comment on this ﬁnding.
We are not aware of any other studies that have directly
compared LEI and non-LEI AEDs, either in people with epilepsy or in
other populations. However, two further case–control studies set in
Denmark have found that the odds ratio for the association between
fracture and AED use was greater for LEI AEDs than non-LEI
AEDs.10,11 From observed decreases in bone density mineral density
with LEI AED treatment, the suggested relative risk for any fracture is
in the region of 1.2–1.3,3 which is in agreement with our ﬁndings.
Previous studies have found that cumulative AED use has a dose
response relationship to fracture risk.21 We could not reliably
determine the duration of AED use in our cohort, so we did not
examine whether a dose response relationship exists for LEI AEDs.
However, the majority of participants had epilepsy for more than 2
years at start of follow-up and most remained on initial AED, so the
observed increase in fracture risk may reﬂect the impact of long
rather than short term exposure.
4.2. Limitations
Initial drug selection in epilepsy is often the responsibility of
specialists in neurology, internal medicine, psychiatry, paediatrics
or elderly care. Since continuation of AEDs is largely managed by
primary care physicians in the UK, most exposure should be
captured using primary care prescriptions that are generated using
the computer software and automatically recorded in the medical
record. However, overestimation of exposure may have occurred if
participants did not actually use the prescription to obtain the
medication or due to poor adherence. This exposure misclassiﬁca-
tion could attenuate the hazard ratio for the association between
LEI AEDs and fracture.
As this study included people who had been diagnosed with
epilepsy and received treatment with AEDs before start of follow-
up, it was not possible to reliably determine the duration of AED
use. Restriction to newly diagnosed patients would have allowed
examination of duration. However, this would have limited the
study to patients with short duration of epilepsy, who may not be
representative of the wider population of people with epilepsy, and
also reduced study power considerably.
This study examined all fractures rather than restricting to ﬁrst
fracture events. To account for recurrent fractures, regression
models allowed the hazard of fracture to differ between those who
had experienced fracture events and those who had not, but it was
assumed that the impact of LEI AED on fracture risk was similar in
both groups. Examination of the hazard ratio for ﬁrst fractures
could have explored this issue, but this would have excluded many
older participant as by age 45 years more than 50% of men and 30%
of women in England have previously experienced a fracture.22
A further limitation is that it was not possible to adjust for some
predictors of fracture, such as dietary calcium or sunlight exposure,
since these details are not commonly recorded in GPRD medical
records. It also was not possible to differentiate between epilepsy
type, as this information was not recorded. Therefore there may be
unmeasured differences between AED treatment groups, such as
greater number of patients with localization related epilepsies in
the LEI AED group. For these reasons, it is not possible to rule out
uncontrolled confounding as an explanation for the association
between LEI AEDs and fracture. However, the detailed medical
record enabled ascertainment of diagnoses, referrals and pre-
scriptions, which allowed adjustment for many potential con-
founders, such as prior diagnosis of osteoporosis, duration of
epilepsy and number of previous AEDs.
5. Conclusion
This study found that LEI AEDs are associated with higher
fracture risk in comparison to non-LEI AEDs. This suggests that it
may be useful to consider minimization of fracture risk when
determining choice of AED. Minimizing the risk of osteoporotic
hip fracture may be particularly important because these
fractures can have severe consequences, including ongoing hip
pain,23 loss of independence,1,24 and increased mortality.24
Current UK guidelines on the treatment of epilepsy include
limited recommendations based on the possible effects of AED
medications on bone health. The National Institute for Clinical
Excellence (NICE) recommend tests of bone metabolism every 2–5
years for adults taking LEI AEDs.25 The Medicines and Healthcare
products Regulatory Agency (MHRA) has recommended consid-
ering vitamin D supplementation for at risk patients treated with
the LEI AEDs carbamazepine, phenytoin, primidone, and also
sodium valproate.26 Scottish Intercollegiate Guidelines Network
(SIGN) guidelines recommend that patients taking both LEI and
non-LEI AEDs should receive dietary and lifestyle advice to reduce
osteoporosis risk.27
Guidance from the USA has suggested that for newly diagnosed
people with epilepsy over the age of 60, use of LEI AEDs should not
be started unless at least two other AEDs have been unsuccessful in
stopping seizures or have caused intolerable adverse effects.28 It
may be useful to consider similar prescribing guidelines in the UK,
in order to minimize the additional burden of fracture from the use
of LEI AEDs. However, in order to make ﬁrm recommendations
further information is needed on the safety of alternatives,
particularly valproate and newer AEDs. Since it may not always
be possible to avoid prescribing LEI AEDs to people thought to be at
high risk of fracture, studies are also urgently needed to examine
strategies to maintain and improve bone health in people who
need to be treated with LEI AEDs.
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